NCT03531060View on ClinicalTrials.gov

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 8, 2016

Primary Completion Date

April 12, 2017

Study Completion Date

April 12, 2017

Conditions
Parkinson Disease
Interventions
DRUG

IRL790

IRL790 capsule 10 mg

DRUG

Placebo

Placebo capsule

Sponsors
All Listed Sponsors
lead

Integrative Research Laboratories AB

INDUSTRY

NCT03531060 - A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia | Biotech Hunter | Biotech Hunter